Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
A 2024 ASCRS Annual Meeting symposium featured quick-hit tips from glaucoma specialists. Panelists were asked to share a 1-minute pearl in a variety of categories and included Sarah Van Tassel, MD, Kuldev Singh, MD, MPH, Douglas Rhee, MD, Lorraine Provencher, MD, and Christopher Teng, MD, MBA.
➤ Topline results from trial for biologic eye drop for dry eye ➤ First patient dosed in Phase 3 trial evaluating oral non-opioid sedation ➤ First patient dosed in retinitis pigmentosa gene therapy trial ➤ Clinical program for IOP-lowering drug discontinued ➤ ASCRS news and events
One physician shared how switching out the typical top on a glaucoma medication for the Nanodropper Adaptor, a screw-on cap that delivers a smaller drop of the medication, has helped her glaucoma patients from a compliance standpoint.
➤ FDA grants 510(k) indication expansion for MIGS tool ➤ FDA approves biosimilar for aflibercept ➤ De Novo Marketing Authorization granted for home OCT device ➤ Consensus guidelines for suprachoroidal drug delivery ➤ ASCRS news and events
➤ Topline results for investigational first-in-class dry eye drop ➤ Dosing complete in second cohort of Stargardt disease gene therapy trial ➤ Enrollment complete for Phase 2 acute optic neuritis trial ➤ Enrollment complete for Phase 1/2a trial evaluating neovascular AMD therapy ➤ ASCRS news and events
➤ CRISPR gene-editing trial shows ‘exciting potential’ ➤ Study: laser vision correction clinics missing opportunities ➤ Broad-based protection observed with investigational geographic atrophy therapy ➤ FDA accepts IND for diabetic macular edema therapy ➤ Phase 2 trial for non-proliferative diabetic retinopathy therapy does not meet primary endpoint ➤ ASCRS news and events
➤ One-year data from first-in-human drug eluting IOL ➤ Company begins two Phase 2 studies for glaucoma treatment ➤ First patient dosed in allogenic cell therapy trial ➤ Company outlines resubmission plan for reproxalap NDA ➤ Safety information for the upcoming solar eclipse ➤ Upcoming company presentations at Eyecelerator and the ASCRS Annual Meeting ➤ Complimentary access to video journal ➤ ASCRS news and events
➤ Positive topline results in trial for retinitis pigmentosa treatment ➤ Phase 2 trial for first-in-human inflammatory dry eye therapy ➤ Landmark clinical trial shows non-inferiority of Nanodropper technology ➤ Dosing complete for gene therapy aiming to help patients with Leber congenital amaurosis ➤ Enrollment begins for secondary IOL technology Phase 1 pivotal trial ➤ Strategic alignment news ➤ ASCRS news and events
Anti-VEGF intravitreal injections may have some effect on the success of glaucoma procedures, and a retina specialist and glaucoma specialist agreed that this is dependent on the patient.
Glaucoma Editor Manjool Shah, MD, reflected on the journey of his colleagues over the last 50 years and shared what readers can expect in the Glaucoma section of the issue.
Get the latest ophthalmology news delivered to your inbox every Friday.